MICLAST*DERM POWDER FL 30G 1%

MICLAST 1% cream
MICLAST 1% cutaneous powder
MICLAST 1% cutaneous solution
Ciclopirox olamine

What it is and what it is used for
MICLAST contains the active ingredient ciclopirox olamine.
MICLAST belongs to a group of medicines called antifungals.
MICLAST is used for certain fungal skin infections (cutaneous mycoses caused by sensitive fungi).

What you need to know before taking the medicine
Do not use MICLAST
• if you are allergic to ciclopirox olamine or any of the other ingredients of this medicine (listed in section 6);
• on wounds in the case of MICLAST cutaneous powder.

Warnings and precautions
Talk to your doctor or pharmacist before using MICLAST.

Avoid contact with eyes.

Use MICLAST with caution and under direct medical supervision:
• if you are simultaneously being treated with other antifungals administered by routes other than the cutaneous route (systemic antifungal treatment);
• if you have previously been diagnosed with severe immune deficiencies (immunosuppression);
• if your immune system is compromised, such as in the case of transplantation and HIV infection;
• if you are diabetic.

The use, especially if prolonged, of topical products can cause allergic reactions (sensitization). In this case, stop the treatment and consult your doctor.
During treatment, carefully observe the hygiene measures recommended by your doctor and/or pharmacist.
If you have a Candida infection, do not use an acidic soap, as it can encourage its proliferation.

Cream:
Avoid contact with mucous membranes.
Do not apply to wounds.

Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may occur with the use of MICLAST:

Cream and cutaneous solution
Common side effects (may affect up to 1 in 10 people)
Worsening of symptoms in the application area:
• burning sensation;
• redness;
• itching.
These side effects occur during the first applications and are temporary. It is not necessary to discontinue treatment.

Uncommon side effects (may affect up to 1 in 100 people)
• general allergic reactions (hypersensitivity);
• blisters in the application area.
Stop treatment and consult your doctor as soon as possible if these side effects occur.

Side effects with unknown frequency (frequency cannot be estimated from the available data)
• local skin inflammations, such as eczema and contact dermatitis.

No side effects affecting the entire body are known. However, this possibility cannot be excluded in patients undergoing prolonged treatment on large surfaces, on wounds, on mucous membranes, or in the case of using bandages that do not allow the dispersion of the medicine (occlusive dressing).

Cutaneous powder
Side effects with unknown frequency (frequency cannot be estimated from the available data)
• skin inflammations, such as eczema and contact dermatitis;
• local allergic skin reactions, such as stinging, irritation, redness, erythema, itching and/or numbness in the application area.

Following the instructions in this leaflet reduces the risk of side effects.

Reporting of side effects
If you get any side effects, including any not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse.
By reporting side effects you can help provide more information on the safety of this medicine.